Diagnostic assessment of endothelial function in metabolic syndrome and coronary heart disease
https://doi.org/10.15829/1728-8800-2011-2-81-87
Abstract
Aim. To study the endothelial status, endothelial relaxation and constriction reserve, inflammation markers, and adipokines in men with metabolic syndrome (MS) and various forms of coronary heart disease (CHD).
Material and methods. In total, 236 male patients (mean age 56,5±2,07 years) were followed up. Serum levels of NO metabolites (NOnˉ), endothelin-1 (ET-1), and C-reactive protein (CRP) were measured, as well as the levels of cytokine system components (interleukin (IL) 6 and 10), tumor necrosis factor (TNF) alpha, and adipokines (leptin and adiponectin).
Results. Endothelial dysfunction was manifested in reduced levels of NO metabolites in MS and additional increase of serum ET-1 concentration in CHD. Serum CRP levels were increased in MS and CHD, being maximal in patients with Q-wave myocardial infarction (MI). In MI patients, the levels of TNF-alpha and IL-10 were decreased, while IL-6 concentration was elevated. Leptin concentration was increased in participants with MS only, or the combination of MI and MS. Adiponectin levels were decreased in MI patients, regardless of MS presence or absence.
Conclusion. The combination of MS and CHD was characterised by endothelial dysfunction. Serum inflammatory activity (increased CRP levels) was elevated in MS and was maximal in Q-wave MI. Serum levels of adipokines were dependent on MS presence or absence, with increased leptin concentration both at the risk factor stage and the Q-wave MI stage.
About the Authors
V. A. Nevzorova
Vladivostok State Medical University
Russian Federation
Vladivostok
Russian Federation
Vladivostok
O. V. Nastradin
Vladivostok State Medical University
Russian Federation
Vladivostok
Russian Federation
Vladivostok
O. G. Pomogalova
City Clinical Hospital No. 1
Russian Federation
Vladivostok
Russian Federation
Vladivostok
E. S. Potapova
Vladivostok State Medical University
Russian Federation
Vladivostok
Russian Federation
Vladivostok
References
1. Арутюнов Г.П., Костюкевич О.И., Хадышьян Г.Г. Немедикаментозные методы коррекции системного воспаления при заболеваниях сердечно-сосудистой системы. Сердце 2005; 5(23): 268-72.
2. Бернштейн Л.М. Эндокринная функция жировой ткани. Природа 2005; 3: 40-51.
3. Богова О.Т., Чукаева И.И. Инфаркт миокарда. Воспаление и прогноз. РКЖ 2003; 4(42): 95-7.
4. Гомазков О.А. Эндотелин в кардиологии: молекулярные, физиологические и патологические аспекты (обзор). Кардиология 2001;2: 50-8.
5. Константинов В.О., Сайфулина Я.Р. Метаболический синдром – болезнь или случайный набор риск-факторов. Артер гиперт 2007; 13(3): 195-6.
6. Котовская Ю.В. Метаболический синдром: прогностическое значение и современные подходы к комплексной терапии. Сердце 2005; Т. 4, № 5(23): 236-42.
7. Мамедов М.Н. Как предотвратить риск развития ишемической болезни сердца и сахарного диабета? М.: Пагри 2006; 50 с.
8. Buettner HJ, Mueller C, Gick M, et al. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J 2007; 28: 1694-701.
9. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007; 28: 850-6.
10. Franks PW, Olsson T. Metabolic syndrome and early death: getting to the heart of the problem. Hypertension 2007; 49: 10-2.
11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive summary. Circulation 2005; 112: 2735-52.
12. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement of the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2005; 28: 2289-304.
13. Kingwell ВА. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 2000; 12(14): 1685-96.
14. Tikhonoff V, Casiglia E. Metabolic syndrome: nothing more than constellation? Eur Heart J 2007; 28: 780-1.
15. Votruba SB, Jensen MD. Regional fat deposition as a factor in FFA metabolism. Ann Rev Nutr 2007; 27: 149-63.
16. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts cardiovascular mortality: a 13-year followup study in elderly non-diabetic Finns. Eur Heart J 2007; 28: 857-64.
17. Weghuber D, Zaknun D, Nasel C, et al. Early cerebrovascular disease in a 2-year-old with extreme obesity and complete metabolic syndrome due to feeding of excessively high amounts of energy. Eur J Pediatr 2007; 166: 37-41.
Review
For citations:
Nevzorova V.A., Nastradin O.V., Pomogalova O.G., Potapova E.S. Diagnostic assessment of endothelial function in metabolic syndrome and coronary heart disease. Cardiovascular Therapy and Prevention. 2011;10(2):81-87. (In Russ.) https://doi.org/10.15829/1728-8800-2011-2-81-87
Views:
573
Email this article 
